Cardiovascular Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cordis Corporation
Low adverse events incidence with sirolimus-eluting coronary stent, study shows
December 7th, 2004
Data presented at the 2004 American Heart Association Scientific Sessions further documented the low incidence of major adverse cardiac events (MACE) and stent thrombosis (blood clots) associated with the CYPHER sirolimus-eluting coronary stent. The overall MACE rate at 6 months for the drug-eluting stent was 3.1% in the 11,920 patients evaluated for the study, including men and women of different ages and ethnicities and with varying health status, including patients with diabetes. MACE, which is a critical measurement of a drug-eluting stent's safety and efficacy, is a composite endpoint that typically includes such factors as target lesion...
Source: Cardiovascular Business Week (2004-12-07)
|
